Neuropeptides as a Treatment for SCN1A-derived Epilepsy
Вставка
- Опубліковано 5 лип 2022
- Presented as part of the the 2022 Dravet Syndrome Foundation (DSF) Conference, Dr. Andrew Escayg of Emory University describes experiments using a mouse model of SCN1A-epilepsy to develop and assess chemicals called neuropeptides as a possible treatment approach using specialized methods to allow the neuropeptides to reach the brain.
